ArticleCureus2025
Diagnosis and Treatment of Plasmablastic Lymphoma in an Immunocompetent Patient: A Report of a Rare Case.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasmablastic lymphoma (PBL) is a rare and aggressive subtype of diffuse large B-cell lymphoma (DLBCL), often associated with immunodeficiency states such as HIV infection. However, PBL can also occur in HIV-negative individuals, where it exhibits diverse anatomical involvement and poorer prognosis. This case presents a 50-year-old HIV negative male patient with progressive lower limb weakness and numbness due to a thoracic paravertebral lesion extending from T1 to T6, causing compressive myelopathy. Imaging raised concerns for malignancy, and histopathology confirmed PBL with positivity on IHC for CD38, CD138, and Cyclin D1. Given its aggressive nature, early intervention was critical. The patient underwent surgical decompression via T2-T6 laminectomy followed by chemotherapy with the EPOCH regimen (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin). After two cycles, significant symptomatic improvement was observed. HIV-negative PBL is associated with poor prognosis and high relapse rates, necessitating aggressive treatment and close monitoring. This case highlights the challenges in diagnosing and managing HIV-negative PBL, emphasizing the importance of multimodal treatment strategies, including surgical intervention, intensive chemotherapy, and follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.